View:
Download DOC
Download PDF
Download XLS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
 
FORM 6-K
 
 

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
Date of Report: August 19, 2022
 
Commission File Number: 001-39307
  
 
 
Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)
 
 
 

2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)
 
 

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F  ☒            Form 40-F  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
Legend Biotech Announces Participation in Upcoming Investor Conferences

On August 19, 2022, Legend Biotech Corporation (“Legend Biotech”) issued a press release announcing its participation in upcoming investor conferences.

The press release announcing the upcoming investor conferences is attached to this Form as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Form 6-K, excluding Exhibit 99.1, is hereby incorporated by reference into Legend Biotech’s Registration Statements on Form F-3 (Registration Nos. 333-257625 and 333-257609) and Legend Biotech’s Registration Statement on Form S-8 (Registration No. 333-239478).


EXHIBIT INDEX

Exhibit              Title

99.1                    Press Release, dated August 19, 2022
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
LEGEND BIOTECH CORPORATION
 
 
 
Date: August 19, 2022
By:
/s/ Ying Huang
 
Name:
Ying Huang, Ph.D.
 
Title:
Chief Executive Officer
 
Exhibit 99.1

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J.--(BUSINESS WIRE)--August 19, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

Event: Citi's 17th Annual BioPharma Conference
Location: Boston, Massachusetts
Fireside Chat Date & Time: Wednesday, September 7, 2022 at 11:20am ET
Presenter: Ying Huang, Ph.D., CEO

Event: 2022 Wells Fargo Healthcare Conference
Location: Boston, Massachusetts
Fireside Chat Date & Time: Thursday, September 8, 2022 at 2:35pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Morgan Stanley Global Healthcare Conference 2022
Location: New York, New York
Fireside Chat Date & Time: Monday, September 12, 2022 at 3:40pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Jefferies Cell and Genetic Medicine Summit
Location: New York, New York
Date: September 29 & 30, 2022

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Contacts

Investor Contacts:
Joanne Choi, Senior Manager, Investor Relations, Legend Biotech
joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com

Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025